I respectfully disagree. If Harvard did not see so

I respectfully disagree. If Harvard did not see something meaningful in the data from the first cohort in cycle one (let's assume no changes in p21), what's the point of continuing treatment at the lowest dosage level? That's addtional 84 blood samples to collect and analyze per cycle. A lot of time and work are involved here. Andrew has been correct about previous delays, so I take his words more seriously than others. Again, JMHO.